ClinicalTrials.Veeva

Menu
The trial is taking place at:
F

Faculdade de Medicina de Botucatu | Unesp

Veeva-enabled site

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)

Lilly logo

Lilly

Status and phase

Enrolling
Phase 3

Conditions

Juvenile Idiopathic Arthritis

Treatments

Drug: Baricitinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT03773965
16278
I4V-MC-JAHX (Other Identifier)
2017-004471-31 (EudraCT Number)

Details and patient eligibility

About

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Enrollment

190 estimated patients

Sex

All

Ages

1 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants must have completed a previous study of baricitinib for the treatment of JIA.

Exclusion criteria

  • Participants must not have had a permanent discontinuation of baricitinib in the prior study.
  • Participants must have not developed an allergy to baricitinib.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

190 participants in 1 patient group

Baricitinib
Experimental group
Description:
Baricitinib given orally.
Treatment:
Drug: Baricitinib

Trial contacts and locations

91

Loading...

Central trial contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems